Immutep to Participate in Upcoming Investor Conferences
Immutep (ASX: IMM; NASDAQ: IMMP), a late-stage immunotherapy company focused on cancer and autoimmune diseases, has announced its participation in three major upcoming investor conferences.
The company will attend the Jones Healthcare and Technology Innovation Conference in Las Vegas on April 9, 2025, at 4:30 pm ET, followed by the Citizens Life Sciences Conference in New York on May 8, 2025, at 1:00 pm ET. Additionally, Immutep will participate in the Jefferies Global Healthcare Conference in New York on June 4-5, 2025, with detailed presentation information to be released later on the company's website.
Immutep (ASX: IMM; NASDAQ: IMMP), un'azienda di immunoterapia in fase avanzata focalizzata su cancro e malattie autoimmuni, ha annunciato la sua partecipazione a tre importanti conferenze per investitori in programma.
L'azienda parteciperà alla Jones Healthcare and Technology Innovation Conference a Las Vegas il 9 aprile 2025, alle 16:30 ET, seguita dalla Citizens Life Sciences Conference a New York l'8 maggio 2025, alle 13:00 ET. Inoltre, Immutep parteciperà alla Jefferies Global Healthcare Conference a New York il 4-5 giugno 2025, con informazioni dettagliate sulla presentazione che saranno rilasciate successivamente sul sito web dell'azienda.
Immutep (ASX: IMM; NASDAQ: IMMP), una empresa de inmunoterapia en etapa avanzada centrada en el cáncer y enfermedades autoinmunes, ha anunciado su participación en tres importantes conferencias para inversores que se aproximan.
La empresa asistirá a la Jones Healthcare and Technology Innovation Conference en Las Vegas el 9 de abril de 2025, a las 4:30 p.m. ET, seguida de la Citizens Life Sciences Conference en Nueva York el 8 de mayo de 2025, a la 1:00 p.m. ET. Además, Immutep participará en la Jefferies Global Healthcare Conference en Nueva York del 4 al 5 de junio de 2025, con información detallada sobre la presentación que se publicará más adelante en el sitio web de la empresa.
Immutep (ASX: IMM; NASDAQ: IMMP)은 암 및 자가면역 질환에 초점을 맞춘 후기 단계 면역 요법 회사로, 다가오는 세 가지 주요 투자자 회의에 참여한다고 발표했습니다.
회사는 2025년 4월 9일 오후 4시 30분 ET에 라스베이거스에서 열리는 Jones Healthcare and Technology Innovation Conference에 참석하며, 이어서 2025년 5월 8일 오후 1시에 뉴욕에서 열리는 Citizens Life Sciences Conference에 참석할 예정입니다. 또한, Immutep은 2025년 6월 4일부터 5일까지 뉴욕에서 열리는 Jefferies Global Healthcare Conference에도 참여하며, 발표에 대한 자세한 정보는 나중에 회사 웹사이트에 공개될 예정입니다.
Immutep (ASX: IMM; NASDAQ: IMMP), une entreprise d'immunothérapie en phase avancée axée sur le cancer et les maladies auto-immunes, a annoncé sa participation à trois grandes conférences pour investisseurs à venir.
L'entreprise assistera à la Jones Healthcare and Technology Innovation Conference à Las Vegas le 9 avril 2025 à 16h30 ET, suivie de la Citizens Life Sciences Conference à New York le 8 mai 2025 à 13h00 ET. De plus, Immutep participera à la Jefferies Global Healthcare Conference à New York les 4 et 5 juin 2025, avec des informations détaillées sur la présentation qui seront publiées ultérieurement sur le site Web de l'entreprise.
Immutep (ASX: IMM; NASDAQ: IMMP), ein Unternehmen für Immuntherapie in der späten Phase, das sich auf Krebs und Autoimmunerkrankungen konzentriert, hat seine Teilnahme an drei wichtigen bevorstehenden Investorenkonferenzen angekündigt.
Das Unternehmen wird am Jones Healthcare and Technology Innovation Conference in Las Vegas am 9. April 2025 um 16:30 Uhr ET teilnehmen, gefolgt von der Citizens Life Sciences Conference in New York am 8. Mai 2025 um 13:00 Uhr ET. Darüber hinaus wird Immutep an der Jefferies Global Healthcare Conference in New York vom 4. bis 5. Juni 2025 teilnehmen, wobei detaillierte Präsentationsinformationen später auf der Website des Unternehmens veröffentlicht werden.
- None.
- None.
SYDNEY, AUSTRALIA , April 02, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces its management will present and participate in one-on-one meetings at the following investor conferences:
| Jones Healthcare and Technology Innovation Conference | ||
| Location: | Las Vegas, NV | |
| Date: | Wednesday, 9 April 2025 | |
| Time: | 4:30 pm ET | |
| The Citizens Life Sciences Conference | ||
| Location: | New York, NY | |
| Date: | Thursday, 8 May 2025 | |
| Time: | 1:00 pm ET | |
| Jefferies Global Healthcare Conference | ||
| Location: | New York, NY | |
| Date: | Wednesday & Thursday, 4 & 5 June 2025 | |
Additional information for the Jefferies presentation will be made available closer to the conference on the Events page within the Investors & Media section of Immutep’s website.
About Immutep
Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.
Australian Investors/Media:
Catherine Strong, Sodali & Co.
+61 (0)406 759 268; catherine.strong@sodali.com
U.S. Media:
Chris Basta, VP, Investor Relations and Corporate Communications
+1 (631) 318 4000; chris.basta@immutep.com
FAQ
What investor conferences will Immutep (IMMP) attend in 2025?
When and where is Immutep (IMMP) presenting at the Jones Healthcare Conference?
What is the schedule for Immutep's (IMMP) presentation at the Citizens Life Sciences Conference?
Where can investors find information about Immutep's (IMMP) presentation at the Jefferies Conference?
